Bluebird Bio Inc (NASDAQ:BLUE) just attracted another bull to its biotech table, with Canaccord analyst John Newman believing the company’s collaboration with Celgene on its bb2121 therapy for relapsed/refractory multiple myeloma looks all the more captivating down the line.